Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients:: deleterious role of glucocorticoid therapy at the lumbar spine

被引:71
作者
Jardinet, D
Lefèbvre, C
Depresseux, G
Lambert, M
Devogelaer, JP
Houssiau, FA [1 ]
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Dept Rheumatol, Brussels, Belgium
[2] Catholic Univ Louvain, Clin Univ St Luc, Gen Internal Med Dept, Brussels, Belgium
关键词
SLE; osteoporosis; glucocorticoids; BMD; longitudinal; pre-menopausal females;
D O I
10.1093/rheumatology/39.4.389
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate whether bone loss occurs over time in pre-menopausal systemic lupus erythematosus (SLE) patients. Methods. We performed a longitudinal bone mineral density (BMD) analysis in a group of 35 pre-menopausal female SLE patients. Lumbar spine and hip (total and sub-regions) BMDs were measured twice 21 +/- 11 (mean +/- S.D.) months apart by dual-energy X-ray absorptiometry. Results. In the whole cohort of SLE patients, significant bone loss was observed at the lumbar spine (-1.22%/yr) but not at the total hip. Further analyses indicated that lumbar spine bone loss (-2.12%/yr) occurred exclusively in the subgroup of patients who had taken a mean prednisolone daily dose >7.5 mg between the two BMD measurements. Moreover, bone loss was more important in patients who had previously received a cumulative prednisolone dose less than or equal to 5 g by the time of their first BMD evaluation. Conclusions. These results, by demonstrating a loss of lumbar spine bone over lime in premenopausal SLE patients given glucocorticoid (GC) therapy, strongly support the use of preventive treatment to minimize GC-induced osteoporosis in pre-menopausal female SLE patients given prednisolone daily doses >7.5 mg.
引用
收藏
页码:389 / 392
页数:4
相关论文
共 19 条
[1]   Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial [J].
Boutsen, Y ;
Jamart, J ;
Esselinckx, W ;
Stoffel, M ;
Devogelaer, JP .
CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (04) :266-271
[2]   OSTEOPOROSIS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
COMPSTON, JE ;
JUDD, D ;
CRAWLEY, EO ;
EVANS, WD ;
EVANS, C ;
CHURCH, HA ;
REID, EM ;
RHODES, J .
GUT, 1987, 28 (04) :410-415
[3]  
DEDEUXCHAISNES CN, 1984, ADV EXP MED BIOL, V171, P209
[4]  
DEVOGELAER JP, 1987, CURRENT RES OSTEOPOR, P36
[5]   LOSS OF BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FORMIGA, F ;
MOGA, I ;
NOLLA, JM ;
PAC, M ;
MITJAVILA, F ;
ROIGESCOFET, D .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (04) :274-276
[6]   Sequential study of bone mineral density in patients with systemic lupus erythematosus [J].
Formiga, F ;
Nolla, JM ;
Moga, I ;
RoigEscofet, D .
ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (11) :857-857
[7]  
Hansen M, 1998, SCAND J RHEUMATOL, V27, P197
[8]  
Houssiau FA, 1996, BRIT J RHEUMATOL, V35, P244
[9]   LOSS OF TRABECULAR BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
KALLA, AA ;
FATAAR, AB ;
JESSOP, SJ ;
BEWERUNGE, L .
ARTHRITIS AND RHEUMATISM, 1993, 36 (12) :1726-1734
[10]  
Kipen Y, 1997, J RHEUMATOL, V24, P1922